Jul 04, 2026 12:56:25 IST
Monarch brokerage Networth Capital remains constructive on a handful of companies it believes offer favorable risk-reward amid an improving business outlook. Here’s a look at the stocks on his radar and what’s driving his positive outlook.
ETMarkets.com
The company has a Buy rating and price target of Rs 724, implying 17.3% upside potential. It expects Pricol to generate a revenue CAGR of 17%, an EBITDA CAGR of 16% and a PAT CAGR of 19% over FY26-28, driven by the revenue mix of its DIS business and robust growth in the P3L business. The brokerage also expects near-term margin pressure to ease from Q2FY27E.
ETMarkets.com
With a Buy rating and target price of Rs 340, Monarch sees an upside potential of 24.1% from current market levels. The brokerage expects Redington to post a revenue CAGR of 15.7%, EBITDA CAGR of 16.9% and PAT CAGR of 7.3% over FY25-28E. The brokerage expects EBITDA margins to gradually improve, supported by higher contribution from cloud, technology solutions and services.
ETMarkets.com
The brokerage has a Buy rating and a price target of Rs 1,060 on the stock, suggesting an upside potential of 12.8%. Analysts expect the company to post a revenue CAGR of 12%, EBITDA CAGR of 17% and PAT CAGR of 19% over FY26-FY28E, driven by a recovery in exports, strong domestic demand and growth in non-automotive orders. The brokerage also expects EBITDA margins to improve to 17% and return ratios to exceed 15%.
ETMarkets.com
With a Buy rating and a target price of Rs 1,680, the brokerage implies an upside potential of 26.9%. Monarch Network Capital expects Travel Food Services to generate a revenue CAGR of 13%, an EBITDA CAGR of 10% and a PAT CAGR of 12% over FY26-28E. The brokerage expects EBITDA margins to normalize to around 37% from the high of 39.4%, due to high input costs and expenses related to ramping up newly commissioned units.
ETMarkets.com
Monarch Network Capital has a Buy rating and a price target of Rs 330, indicating a potential upside of 14.2%. The brokerage expects the company to post a revenue CAGR of 17%, EBITDA CAGR of 20% and PAT CAGR of 41% over FY26-28E, driven by a strong product launch pipeline. The brokerage expects EBITDA margins to remain between 20% and 22% during the period, supported by merger synergies and growth in its higher-margin human and pet health businesses.
(Disclaimer: The recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
ETMarkets.com